ModraDoc006 , an oral docetaxel formulation in combination with ritonavir ( ModraDoc006 /r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study-Reference-Cited by-同舟云学术

ModraDoc006 , an oral docetaxel formulation in combination with ritonavir ( ModraDoc006 /r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

Published:2021-03-12 Issue:4 Volume:4 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Vermunt Marit A. C.¹^ORCID,Robbrecht Debbie G. J.²^ORCID,Devriese Lot A.³,Janssen Julie M.⁴,Thijssen Bas⁴,Keessen Marianne⁵,Eijk Maarten⁴^ORCID,Kessels Rob⁶,Eskens Ferry A. L. M.²,Beijnen Jos H.⁴⁵⁷,Mehra Niven⁸,Bergman Andries M.⁹

Affiliation:

1. Department of Clinical Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands

2. Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam The Netherlands

3. Department of Medical Oncology University Medical Center Utrecht Utrecht The Netherlands

4. Department of Pharmacy and Pharmacology The Netherlands Cancer Institute Amsterdam The Netherlands

5. Modra Pharmaceuticals B.V. Amsterdam The Netherlands

6. Department of Biometrics The Netherlands Cancer Institute Amsterdam The Netherlands

7. Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

8. Department of Medical Oncology Radboud University Medical Center Nijmegen The Netherlands

9. Department of Medical Oncology and Oncogenomics The Netherlands Cancer Institute Amsterdam The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1367

Reference22 articles.

1. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2. Docetaxel administration schedule: From fever to tears? A review of randomised studies

3. Patient preferences for oral versus intravenous palliative chemotherapy.

4. Managing taxane toxicities

5. Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer;European Journal of Cancer;2024-05

2. Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment;Cancer Chemotherapy and Pharmacology;2024-03-08

3. Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel;Cancer Drug Resistance;2024-01-31

4. Is Higher Docetaxel Clearance in Prostate Cancer Patients Explained by Higher CYP3A? An In Vivo Phenotyping Study with Midazolam;The Journal of Clinical Pharmacology;2023-10-26

5. Docetaxel as a Model Compound to Promote HDL (High-Density Lipoprotein) Biogenesis and Reduce Atherosclerosis;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-05